Skip to Main Content
Contact Us

Catalyst Concludes Acquisition of Acumen Healthcare Solutions

November 18, 2020

Bolsters Database Expertise, Positions Proprietary ‘Flex’ for Future Growth

Wilmington, NC, 18 November 2020 – Catalyst Clinical Research announced today the company has completed the acquisition of Acumen Healthcare Solutions (AHS), a data management software and services company headquartered in Plymouth, Minnesota.

Catalyst CEO Nick Dyer said the AHS acquisition bolsters expansion opportunities for Catalyst Flex, the proprietary functional and resourcing service solution created by Catalyst to fulfill multi-therapeutic operations and staffing needs for clients.

“We will immediately add more robust database building and data management services and expand the range of our EDC solutions,” Dyer added. “This acquisition allows AHS customers significantly more access to comprehensive data solutions through Catalyst Flex or a full-service niche-Oncology CRO option with Catalyst Oncology.”

Catalyst Flex is an innovative, “fit for purpose” model that leverages the experience of accomplished clinical research professionals and project-based solutions built on more than 10 years of clinical research experience.

The AHS acquisition adds to Catalyst’s market coverage and growth trajectory, Dyer said. Created in 1997, AHS developed a distinctive process that has the potential to improve all facets of data collection, from the use of forms (e-CRFs) to data cleaning processes. Catalyst will continue to support AHS’s medical device clients in addition to leveraging the product in biopharma trials.

Catalyst welcomes the extensive experience of AHS in creating, designing and managing large clinical databases, said Shannon Villiers, Global Head of Catalyst Data Management. “This acquisition strengthens our ability to offer a variety of EDC solutions to the life sciences industry by establishing, designing and managing large clinical databases.”

This acquisition is the second strategic corporate action by Catalyst in 2020. In August, Catalyst Clinical Research announced a merger with Ce3, Inc. designed to expand its oncology therapeutic expertise. The union created a market leading CRO solution with expertise in study designs to focus on and enhance complex cancer therapies.

About Catalyst 

Catalyst is a clinical development organization providing highly customizable clinical research solutions to the global biopharmaceutical industry. With offices in the US and EU, the company provides global resourcing and functional solutions as well as a full-service CRO offering, the latter focused exclusively on oncology. Catalyst’s flexible service model is built from more than a decade of listening to customers, devising customer-centric solutions and helping them drive breakthrough clinical development studies leveraging Catalyst’s expert teams and innovative technologies.

Catalyst is a portfolio company of NovaQuest Capital Management, LLC, a leading healthcare and life sciences investment firm.